Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability

TheFly reported connected April 7 that Jefferies lowered its terms people connected ABUS from $7.00 to $5.50 portion maintaining a Buy rating. The revision was driven by updated expectations astir the result of Moderna’s entreaty successful ongoing litigation, which could power a imaginable $1.3 cardinal outgo tied to the case. The steadfast adjusted its probability assessment, expanding the likelihood of a Moderna triumph connected appeal, which successful crook reduced its valuation outlook for ABUS.

On March 23, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported its fourth-quarter and full-year 2025 fiscal results and provided a firm update. The institution highlighted its ongoing litigation-related developments, including a colony statement with Moderna and Genevant nether which ABUS is entitled to a information of a $950 cardinal upfront outgo expected successful July 2026, on with imaginable eligibility for an further $1.3 cardinal contingent connected an appellate outcome.

It besides noted continued ineligible proceedings involving its lipid nanoparticle intelligence property. For the year, the concern reported gross of $14.1 million, nett nonaccomplishment of $33.5 million, currency and investments of $91.5 million, and reduced operating expenses driven by restructuring and outgo optimization efforts focused connected its objective pipeline.

Arbutus Biopharma Corporation (NASDAQ:ABUS) is simply a clinical-stage biopharmaceutical institution focused connected processing therapeutics for viral diseases. It is peculiarly known for its enactment successful hepatitis B treatments, utilizing RNA interference and lipid nanoparticle transportation technologies to people and suppress viral replication.

While we admit the imaginable of ABUS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest successful According to Analysts.

Disclosure: None. Follow Insider Monkey connected Google News.